Trial Profile

A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of the efficacy and safety of HYBR-014 as an adjunctive lifestyle intervention for the treatment of overweight/obesity in adults

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 20 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Oct 2022 New trial record
17 May 2019 According to a Shanghai Renhui Biopharmaceutical Co., the entire study will continue through December 2020.
17 May 2019 According to a Shanghai Renhui Biopharmaceutical Co., Ltd, the research was led by Professor Yoshiaki Mu.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com